Sort
10,766 grants matching “checkpoint inhibitor”
Defining the determinants of response and resistance to therapy for Richter's Syndrome
$356,833Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2022 · CA
Transcatheter Intra-Arterial Delivery of Oriented Anti-PD-L1 Immune checkpoint inhibitors Immobilized Nanocarriers for Local Combination Immunotherapy of Hepatocellular Carcinoma
$356,773Dong-Hyun Kim · Northwestern University At Chicago · R01 · FY2025 · CA
Dissecting and targeting oncogenic functions of PAK4 in high-risk rhabdomyosarcoma
$356,758Jason Yustein · Emory University · R01 · FY2025 · CA
Project 4: Activity of CAR T cell Therapy for Patients with Metastatic TNBC
$356,676Gianpietro Dotti · Univ Of North Carolina Chapel Hill · P50 · FY2024 · CA
PRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
$356,625Markus Mãschen · University Of California, San Francisco · R01 · FY2016 · CA
Regulatory Dendritic Cells in Cancer
$356,620Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2019 · CA
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma
$356,587Yi Lin · Mayo Clinic Rochester · R01 · FY2019 · CA
Estrogen receptor beta is a targetable melanoma tumor suppressor
$356,540Craig J Burd · Ohio State University · R01 · FY2025 · CA
Priming pancreatic ductal adenocarcinoma using blood thinners to sensitize the efficacy of checkpoint immunotherapy
$356,500Taslim A Al-Hilal · University Of Texas El Paso · SC1 · FY2022 · GM
Transformation by the NEU Oncogene Product and EGF
$356,480David F Stern · Yale University · R01 · FY2007 · CA
Project 1 - Integrating targeted and immune therapies for BRAF mutant colorectal cancer
$356,409Ryan Bruce Corcoran · Dana-Farber Cancer Inst · P50 · FY2022 · CA
Dietary trans-vaccenic acid enhances anti-tumor immunity
$356,393Jing Chen · University Of Chicago · R01 · FY2024 · CA
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers
$356,379Jonathan Eric Rosenberg · Sloan-Kettering Inst Can Research · P50 · FY2020 · CA
Estrogen receptor beta is a targetable melanoma tumor suppressor
$356,359Craig J Burd · Ohio State University · R01 · FY2022 · CA
Molecular mechanisms for bone marrow failure and clonal progression during the innate immune response in Fanconi Anemia
$356,225Elizabeth Ann Eklund · Northwestern University At Chicago · R01 · FY2020 · DK
Project 3: Targeted therapy for splicing factor mutant myeloid malignancies
$356,195Matthew J Walter · Washington University · P50 · FY2025 · CA
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
$356,184Ann Richmond · Vanderbilt University · R01 · FY2022 · CA
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
$356,184Ann Richmond · Vanderbilt University · R01 · FY2023 · CA
Chemical Genetic and Biochemical Studies of Mitotic Proteolysis
$356,167Randall W King · Harvard Medical School · R01 · FY2015 · GM
Chemical Genetic and Biochemical Studies of Mitotic Proteolysis
$356,167Randall W King · Harvard Medical School · R01 · FY2016 · GM
PRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
$356,156Markus Mãschen · University Of California, San Francisco · R01 · FY2015 · CA
Targeting the vasculature to enhance anti-tumor immunity
$356,108Andrew Carl Dudley · University Of Virginia · R01 · FY2022 · CA
Reprogramming of the stromal microenvironment in melanoma progression and therapeutic escape
$355,954Yuhang Zhang · University Of Cincinnati · R01 · FY2023 · CA
Immunotherapeutic targeting of MIF-dependent chaperone activity
$355,907Robert A. Mitchell · University Of Louisville · R01 · FY2023 · CA
Role of intratumoral high endothelial venules in tumor immunity
$355,850Masanobu Komatsu · Johns Hopkins University · R01 · FY2024 · CA